Interrogating Mutant Allele Expression via Customized Reference Genomes to Define Influential Cancer Mutations
AffiliationUniv Arizona, Canc Ctr
Univ Arizona, Dept Mol & Cellular Biol
MetadataShow full item record
PublisherNATURE PUBLISHING GROUP
CitationGrant, A. D., Vail, P., Padi, M., Witkiewicz, A. K., & Knudsen, E. S. (2019). Interrogating Mutant Allele Expression via Customized Reference Genomes to Define Influential Cancer Mutations. Scientific reports, 9(1), 1-15.
RightsCopyright © The Author(s) 2019. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Cre-ative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not per-mitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
Collection InformationThis item from the UA Faculty Publications collection is made available by the University of Arizona with support from the University of Arizona Libraries. If you have questions, please contact us at email@example.com.
AbstractGenetic alterations are essential for cancer initiation and progression. However, differentiating mutations that drive the tumor phenotype from mutations that do not affect tumor fitness remains a fundamental challenge in cancer biology. To better understand the impact of a given mutation within cancer, RNA-sequencing data was used to categorize mutations based on their allelic expression. For this purpose, we developed the MAXX (Mutation Allelic Expression Extractor) software, which is highly effective at delineating the allelic expression of both single nucleotide variants and small insertions and deletions. Results from MAXX demonstrated that mutations can be separated into three groups based on their expression of the mutant allele, lack of expression from both alleles, or expression of only the wild-type allele. By taking into consideration the allelic expression patterns of genes that are mutated in PDAC, it was possible to increase the sensitivity of widely used driver mutation detection methods, as well as identify subtypes that have prognostic significance and are associated with sensitivity to select classes of therapeutic agents in cell culture. Thus, differentiating mutations based on their mutant allele expression via MAXX represents a means to parse somatic variants in tumor genomes, helping to elucidate a gene's respective role in cancer.
NoteOpen access journal
VersionFinal published version
SponsorsNational Institute of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01CA211878]
- IDENTIFY CANCER DRIVER GENES THROUGH SHARED MENDELIAN DISEASE PATHOGENIC VARIANTS AND CANCER SOMATIC MUTATIONS.
- Authors: Ma M, Wang C, Glicksberg BS, Schadt EE, Li SD, Chen R
- Issue date: 2017
- Advances in computational approaches for prioritizing driver mutations and significantly mutated genes in cancer genomes.
- Authors: Cheng F, Zhao J, Zhao Z
- Issue date: 2016 Jul
- Oncogene mutations, copy number gains and mutant allele specific imbalance (MASI) frequently occur together in tumor cells.
- Authors: Soh J, Okumura N, Lockwood WW, Yamamoto H, Shigematsu H, Zhang W, Chari R, Shames DS, Tang X, MacAulay C, Varella-Garcia M, Vooder T, Wistuba II, Lam S, Brekken R, Toyooka S, Minna JD, Lam WL, Gazdar AF
- Issue date: 2009 Oct 14
- Epidermal Growth Factor Receptor Mutation (EGFR) Testing for Prediction of Response to EGFR-Targeting Tyrosine Kinase Inhibitor (TKI) Drugs in Patients with Advanced Non-Small-Cell Lung Cancer: An Evidence-Based Analysis.
- Authors: Medical Advisory Secretariat.
- Issue date: 2010
- Tumor transcriptome sequencing reveals allelic expression imbalances associated with copy number alterations.
- Authors: Tuch BB, Laborde RR, Xu X, Gu J, Chung CB, Monighetti CK, Stanley SJ, Olsen KD, Kasperbauer JL, Moore EJ, Broomer AJ, Tan R, Brzoska PM, Muller MW, Siddiqui AS, Asmann YW, Sun Y, Kuersten S, Barker MA, De La Vega FM, Smith DI
- Issue date: 2010 Feb 19